Scholar Rock's second quarter saw the relatively early-stage company post no revenue and a net loss of over $110 million, or ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Operator: Good morning, ladies and gentlemen, and welcome to the Scholar Rock Second Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded […] ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Scholar Rock Holding SRRK -4.80% + Free Alerts has outperformed the market over the past 5 years by 7.22% on an annualized basis producing an average annual return of 21.06%. Currently, Scholar Rock ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need.

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and ...

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 Jul. 21, 2025 8:00 AM ET Scholar Rock Holding Corporation (SRRK) ...

Scholar Rock Holding Corporation (NASDAQ:SRRK – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Scholar Rock in a ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and other severe and debilitating neuromuscular ...